The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

Sun, 29th Mar 2020 20:57

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times
Unemployment in Britain is set to more than double in coming months, despite government efforts to incentivise employers to keep staff. Economists warn that the rise in the second quarter of the year will be even sharper than during the financial crisis in 2008. Nomura, the investment bank, predicts an unemployment rate of 8% in the April-June quarter, rising to 8.5% in the following three months, from 3.9% in January, as GDP falls sharply. The 8% rate would be the equivalent of an additional 1.4 million people unemployed and a total jobless level of 2.75 million. - Sunday Times

Rolls-Royce is facing a cash flow crisis as the collapse in air travel caused by coronavirus sees half of its revenues evaporate, leaving the FTSE 100 engineer scrambling for cash. Within days of the scale of the crisis becoming clear, Rolls drew down ?2.5bn of funding to boost its liquidity to ?7bn. However, with the company depending on its civil aerospace business for half of its ?15.4bn underlying revenue, it is likely to need further funding as the coronavirus crisis drags on. - Sunday Telegraph

Doctors have drawn up plans to infuse British coronavirus patients and their carers with blood plasma harvested from "hyperimmune" people who have recovered from the infection in an attempt to save lives. The experimental treatment will be directed at patients who are admitted to hospital with pneumonia caused by the virus in the hope that it reduces the number who end up on ventilators in intensive care units (ICUs). - Guardian

"Italy's political leaders from Left to Right have erupted in fury over the EU's minimalist, insulting, and cack-handed response to the Covid-19 pandemic, warning that lack of economic solidarity risks pushing the bloc's festering divisions beyond the point of no return. "Don't make a tragic mistake. The whole European edifice risks losing its raison d'etre," said the Italian premier, Giuseppe Conte, demanding a giant Marshall Plan funded on the EU's joint credit card to relaunch the productive system once the current nightmare is over." - Sunday Telegraph

Scores of Britain's best-known high street food and drink chains will go bust by the end of April unless banks provide immediate finance, the head of the hospitality industry has warned. Kate Nicholls, chief executive of the UK Hospitality trade body, said further failures are 'inevitable' after 80- strong restaurant chain Chiquitos - owned by The Restaurant Group, whose chief executive is ex-HBOS bank boss Andy Hornby - and the 73-outlet Carluccio's lined up administrators. Nicholls said short-term loans from banks are vital to cover costs pending the arrival of Government grant packages. - UK Daily Mail

Synairgen, listed on the London Stock Exchange and worth just ?50m, is starting a clinical trial in hospitals across the UK with a drug it hopes will prevent coronavirus sufferers from falling seriously ill. [...] Synairgen will now test the treatment on 100 patients with coronavirus. Half will be given its new drug, half will get a placebo. Results could arrive in as soon as eight weeks, which could pave the way for a fast-tracked pivotal study in a bigger group of patients and rapid approval. - Sunday Times

More News
25 Sep 2014 11:03

Synairgen Swings To Profit On Transformational AstraZeneca Deal

Read more
4 Jul 2014 12:11

Synairgen raises funds to develop AstraZeneca drug

Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is

Read more
4 Jul 2014 07:21

UK MORNING BRIEFING: William Hill Promotes From Within

Read more
4 Jul 2014 06:47

Synairgen Raises GBP5.3 Million In Share Placing At 50 Pence

Read more
15 Jun 2014 12:28

Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property

Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff

Read more
12 Jun 2014 16:37

MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions

LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company BG Group leading the gains as the price of oil climbed amid escalating violence in Iraq.

Read more

12 Jun 2014 10:23

TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014

LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
The initial public offering of B&M European Value Retail SA, the discount retailer chaired by former TescoRead more

12 Jun 2014 08:25

London open: Mining stocks pull FTSE 100 lower ahead of data

- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound

Read more
12 Jun 2014 07:42

AstraZeneca signs licence deal with Synairgen

British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de

Read more
12 Jun 2014 07:36

UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen

LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight.

AstraZeneca is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology

Read more
12 Jun 2014 06:52

AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen

LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections

Read more
20 Mar 2014 12:47

Synairgen Pretax Loss Narrows On Expenses

LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye

Read more
5 Mar 2014 11:31

Synairgen Jumps As It Raises Cash While Progressing Licensing Talks

LONDON (Alliance News) - Synairgen PLC Wednesday said it has raised GBP1.5 million by placing 3.1 million shares at 48 pence each, money it will use for working capital while it progresses current licensing discussions through to a conclusion. In a statement, the respiratory drug discovery

Read more
5 Mar 2014 08:31

UK MORNING BRIEFING: Standard Chartered Profits Fall, Cuts Bonus Pool

LONDON (Alliance News) - Shares have opened mostly lower Wednesday with small-caps out-performing large caps, following Tuesday's relief rally from lowered Ukraine tensions.

Standard Chartered has reported lower 2013 profit and a 15% reduction in its bonus pool, whi

Read more
5 Dec 2012 11:10

Synairgen reports 'significant progress'

Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account